{"disease":{"id":"squamous-cell-carcinomas","name":"squamous cell carcinomas"},"drugs":{"marketed":[{"drug_id":"hydroxyurea","indication_name":"Locally advanced squamous cell carcinomas of the head and neck (excluding lip) in combination with concurrent chemoradiation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HYDROXYUREA","company_name":"","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase","drug_class":"Antimetabolite [EPC]","quality_score":65,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04389112","title":"Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions","phase":"NA","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT04892849","title":"Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT05918510","title":"Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus","phase":"","overall_status":"RECRUITING","enrollment_count":142,"lead_sponsor_name":"Regina Elena Cancer Institute","has_results":false},{"nct_id":"NCT06297811","title":"Myeloprotection With Trilaciclib in Pan-cancer Population","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":132,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04597476","title":"A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":119,"lead_sponsor_name":"Hi-Q Marine Biotech International, Ltd.","has_results":false},{"nct_id":"NCT05482880","title":"Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region","phase":"","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT05103501","title":"Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT06861036","title":"Heterogeneity of Oral Squamous Cell Carcinoma Analysis by Single Cell RNA Sequencing","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT04992559","title":"A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06277791","title":"The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Hospital of Stomatology, Wuhan University","has_results":false},{"nct_id":"NCT06425146","title":"Tobacco, Alcohol and Cancerization of the Oral Mucosa (TACO)","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT06235918","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Xiang Lu","has_results":false},{"nct_id":"NCT04266327","title":"RISI in the Treatment of Recurrent Metastatic SCC of Thoracic Inlet Lymph Nodes","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT02852343","title":"One-step Nucleic Acid Amplification for Detecting Lymph Node Metastasis of Head and Neck Squamous Cell Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT05724329","title":"Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT01706939","title":"The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":true},{"nct_id":"NCT05233436","title":"PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03215810","title":"Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT04142489","title":"In Vivo Damage Induced bu UV in the Epidermis of the Scalp","phase":"NA","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT00627835","title":"Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}